Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares saw an uptick in trading volume on Friday . 4,001 shares traded hands during mid-day trading, an increase of 69% from the previous session’s volume of 2,361 shares.The stock last traded at $336.45 and had previously closed at $335.77.
Genmab A/S Price Performance
The firm has a market capitalization of $21.80 billion, a PE ratio of 16.57 and a beta of 0.95. The company has a fifty day moving average of $256.77 and a 200-day moving average of $222.27.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, beating analysts’ consensus estimates of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million for the quarter, compared to the consensus estimate of $949.06 million.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- Where Do I Find 52-Week Highs and Lows?
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
